AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7787131 — intervention group
Group type: COMPARATOR
Intervention: 10 mg dose of 14C-FOX 988 (gelatin capsules)
Number of subjects: 16
Study 7787131 — intervention group
Group type: COMPARATOR
Intervention: 10 mg dose of 14C-FOX 988 (suspension, 0.5% CMC)
Number of subjects: 16
Study 1693797 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentosan polysulfate sodium (PPS)
Number of subjects: 110
Study 1693797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 7395685 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction-free room during structured activity
Number of subjects: 24
Study 7395685 — intervention group
Group type: COMPARATOR
Intervention: Distractive room during unstructured activity
Number of subjects: 24
Study 31971506 — intervention group
Group type: EXPERIMENTAL
Intervention: Namaste Care intervention
Number of subjects: 32
Study 31971506 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 32
Study 30650448 — intervention group
Group type: EXPERIMENTAL
Intervention: Free access to an iPad, the Internet, and technical assistance during hospitalization.
Number of subjects: 146
Study 28366018 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative smoking education
Number of subjects: 256
Study 28366018 — intervention group
Group type: COMPARATOR
Intervention: Informational smoking education
Number of subjects: 256
Study 25830381 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol 50/25 mcg
Number of subjects: 643
Study 25830381 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol 100/25 mcg
Number of subjects: 643
Study 25830381 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol 200/25 mcg
Number of subjects: 643
Study 25830381 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 643
Study 23908486 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoster vaccine (ZV)
Number of subjects: 2269
Study 23908486 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2269
Study 21378714 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoflavine preparation as energy-correction and antioxidant
Number of subjects: 121
Study 21378714 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of cytoflavine with calcium-D3
Number of subjects: 121
Study 19255206 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment (28 knees)
Number of subjects: 71
Study 19255206 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment (36 knees)
Number of subjects: 71
Study 17594775 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg/calcium-placebo
Number of subjects: 701
Study 17594775 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg/elemental calcium 1000 mg
Number of subjects: 701
Study 17594775 — intervention group
Group type: COMPARATOR
Intervention: Calcium alone
Number of subjects: 701
Study 17594775 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate-containing treatments
Number of subjects: 701
Study 17594775 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg with calcium 1000 mg
Number of subjects: 701
Study 17594775 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 701
Study 16288620 — intervention group
Group type: EXPERIMENTAL
Intervention: Softseal
Number of subjects: 100
Study 16288620 — intervention group
Group type: COMPARATOR
Intervention: LMA-Unique
Number of subjects: 100
Study 12044254 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid‐acting anesthetic agents (midazolam, propofol) for refractory status epilepticus
Number of subjects: 0
Study 12044254 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous digital electroencephalogram (EEG) recordings
Number of subjects: 0
Study 10497778 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse prevention treatment
Number of subjects: 0
Study 10497778 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study 7697252 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (200 micrograms b.i.d.)
Number of subjects: 30
Study 7697252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 7697252 — intervention group
Group type: COMPARATOR
Intervention: Budesonide and Placebo
Number of subjects: 30
Study 2667336 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg before meals
Number of subjects: 9
Study 973984 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin 600 mg
Number of subjects: 0
Study 973984 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid 300 mg
Number of subjects: 0
Study 973984 — intervention group
Group type: COMPARATOR
Intervention: Rifampicin and Isoniazid in combination
Number of subjects: 0
Study 31535524 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative management plus lumbar drain (Group A)
Number of subjects: 60
Study 31535524 — intervention group
Group type: COMPARATOR
Intervention: Conservative management alone (Group B)
Number of subjects: 60
Study 29319769 — intervention group
Group type: EXPERIMENTAL
Intervention: Early physiotherapy program from first postoperative day until hospital discharge
Number of subjects: 63
Study 29319769 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 63
Study 25805280 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted endoscopy
Number of subjects: 34
Study 25805280 — intervention group
Group type: COMPARATOR
Intervention: Nonendoscopic surgery
Number of subjects: 34
Study 23571364 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper alloy surfaces
Number of subjects: 0
Study 23571364 — intervention group
Group type: COMPARATOR
Intervention: Standard ICU rooms
Number of subjects: 0
Study 22105039 — intervention group
Group type: EXPERIMENTAL
Intervention: Lady 4 (2 capsules daily)
Number of subjects: 120
Study 22105039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 19568738 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (n = 17)
Number of subjects: 37
Study 19568738 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment (n = 15)
Number of subjects: 37
Study 19568738 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 30)
Number of subjects: 37
Study 16731088 — intervention group
Group type: EXPERIMENTAL
Intervention: Thorough sonographic oocyte retrieval (n = 34)
Number of subjects: 64
Study 16731088 — intervention group
Group type: COMPARATOR
Intervention: Routine in vitro fertilization retrieval (n = 30)
Number of subjects: 64
Study 14744726 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori treatment (omeprazole, amoxicillin, clarythromycin; n = 122)
Number of subjects: 248
Study 14744726 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo (n = 126)
Number of subjects: 248
Study 14744726 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori treatment (omeprazole, amoxicillin, clarythromycin)
Number of subjects: 248
Study 14744726 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 248
Study 11698315 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. dexamethasone 5 mg
Number of subjects: 120
Study 11698315 — intervention group
Group type: COMPARATOR
Intervention: i.v. metoclopramide 10 mg
Number of subjects: 120
Study 11698315 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 120
Study 9152298 — intervention group
Group type: EXPERIMENTAL
Intervention: Oronasopharyngeal suction (ONPS)
Number of subjects: 30
Study 9152298 — intervention group
Group type: COMPARATOR
Intervention: Control (no ONPS)
Number of subjects: 30
Study 7899582 — intervention group
Group type: EXPERIMENTAL
Intervention: On-line continuous venovenous hemodiafiltration (OL-CVVHDF)
Number of subjects: 0
Study 3591496 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertive training (four sessions)
Number of subjects: 96
Study 3591496 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (career development training sessions)
Number of subjects: 96
Study 30153988 — intervention group
Group type: COMPARATOR
Intervention: Radial access
Number of subjects: 8404
Study 30153988 — intervention group
Group type: COMPARATOR
Intervention: Bivalirudin
Number of subjects: 8404
Study 30153988 — intervention group
Group type: COMPARATOR
Intervention: Post-procedure bivalirudin infusion
Number of subjects: 8404
Study 28358599 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (10 mg/kg up to 500 mg per day for 4 weeks)
Number of subjects: 31
Study 28358599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 28358599 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 31
Study 26237812 — intervention group
Group type: EXPERIMENTAL
Intervention: Omnic (tamsulosin) 0.4 mg once daily for 8 years
Number of subjects: 665
Study 26237812 — intervention group
Group type: COMPARATOR
Intervention: Herbal preparations (Gentos, Tadenan, or Speman)
Number of subjects: 665
Study 26237812 — intervention group
Group type: EXPERIMENTAL
Intervention: Omnic (tamsulosin)
Number of subjects: 665
Study 23369417 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 392
Study 23369417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 392
Study 21418799 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg/benazepril 10 mg once-daily (combination therapy)
Number of subjects: 220
Study 21418799 — intervention group
Group type: COMPARATOR
Intervention: Benazepril 10 mg monotherapy
Number of subjects: 220
Study 18222258 — intervention group
Group type: EXPERIMENTAL
Intervention: CS and VACPB (Group D)
Number of subjects: 100
Study 18222258 — intervention group
Group type: COMPARATOR
Intervention: VACPB alone (Group B)
Number of subjects: 100
Study 18222258 — intervention group
Group type: COMPARATOR
Intervention: CS alone (Group C)
Number of subjects: 100
Study 18222258 — intervention group
Group type: COMPARATOR
Intervention: No CS and no VACPB (Group A)
Number of subjects: 100
Study 17018679 — intervention group
Group type: EXPERIMENTAL
Intervention: Community based fire prevention intervention directed to parents, including in-home visits from fire department personnel who installed free lithium smoke detectors and provided a fire escape plan.
Number of subjects: 0
Study 17018679 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 0
Study 14756429 — intervention group
Group type: EXPERIMENTAL
Intervention: Neo-adjuvant chemotherapy (3 cycles of CEF before and 3 cycles after surgery)
Number of subjects: 101
Study 14756429 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemotherapy (6 cycles of CEF after primary surgery)
Number of subjects: 101
Study 11035354 — intervention group
Group type: EXPERIMENTAL
Intervention: One or two digital cervical examinations
Number of subjects: 950
Study 11035354 — intervention group
Group type: COMPARATOR
Intervention: No digital cervical examinations
Number of subjects: 950
Study 8665632 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (40 micrograms.kg‐1, iv over 2-5 min)
Number of subjects: 50
Study 8665632 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 50
Study 1410095 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of illness (depression and anxiety symptoms)
Number of subjects: 0
Study 1410095 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 0
Study 1410095 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric label
Number of subjects: 0
Study 1410095 — intervention group
Group type: EXPERIMENTAL
Intervention: Good or bad psychosocial context
Number of subjects: 0
Study 1410095 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous experience in psychiatry or other vocational training
Number of subjects: 0
Study 3885850 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin-nafcillin
Number of subjects: 179
Study 3885850 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime
Number of subjects: 179
Study 3885850 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock
Number of subjects: 179
Study 31721447 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine 2.4 mg/kg weekly
Number of subjects: 82
Study 31721447 — intervention group
Group type: COMPARATOR
Intervention: Taxane (docetaxel or paclitaxel)
Number of subjects: 82
Study 31721447 — intervention group
Group type: COMPARATOR
Intervention: Taxane
Number of subjects: 82
Study 28816026 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000-mg sustained-release (SR) acetaminophen
Number of subjects: 14
Study 28816026 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500-mg sustained-release (SR) acetaminophen
Number of subjects: 14
Study 27552990 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation (EVLA)
Number of subjects: 140
Study 27552990 — intervention group
Group type: COMPARATOR
Intervention: Mechanochemical ablation (MOCA)
Number of subjects: 140
Study 24612073 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane at 0.75 MAC
Number of subjects: 51
Study 24612073 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane at 1 MAC
Number of subjects: 51
Study 24612073 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane at 1.25 MAC
Number of subjects: 51
Study 24612073 — intervention group
Group type: EXPERIMENTAL
Intervention: SEF90 and BIS
Number of subjects: 51
Study 22949381 — intervention group
Group type: COMPARATOR
Intervention: Hair zinc levels in RW group (162.43 ± 91.52 µg/g)
Number of subjects: 65
Study 22949381 — intervention group
Group type: COMPARATOR
Intervention: Hair selenium levels in RW group (217.37 ± 83.01 µg/g)
Number of subjects: 65
Study 22949381 — intervention group
Group type: COMPARATOR
Intervention: Total antioxidant capacity (TAC) in RW group (1.38 ± 0.14 mmol/L)
Number of subjects: 65
Study 22949381 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of wheezing episodes in RW group
Number of subjects: 65
Study 22949381 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of acute respiratory tract infection (ARTI) episodes in RW group
Number of subjects: 65
Study 21090334 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal acupuncture
Number of subjects: 86
Study 21090334 — intervention group
Group type: COMPARATOR
Intervention: Medication (metformin 250 mg t.i.d. for 1 week, then 500 mg t.i.d. for 6 months)
Number of subjects: 86
Study 21090334 — intervention group
Group type: COMPARATOR
Intervention: Medication (metformin)
Number of subjects: 86
Study 18661264 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% levofloxacin (LVFX) ophthalmic solution applied for 3 days with diluted PI eyewash
Number of subjects: 272
Study 18661264 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% levofloxacin (LVFX) ophthalmic solution applied for 1 day with diluted PI eyewash
Number of subjects: 272
Study 18661264 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% levofloxacin (LVFX) ophthalmic solution applied for 1 hour with diluted PI eyewash
Number of subjects: 272
Study 18661264 — intervention group
Group type: EXPERIMENTAL
Intervention: Diluted PI eyewash
Number of subjects: 272
Study 18661264 — intervention group
Group type: EXPERIMENTAL
Intervention: Diluted PAI eyewash
Number of subjects: 272
Study 15897530 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin (200 mg/d, 200 mg twice daily, or 200 mg 3 times daily)
Number of subjects: 210
Study 15897530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 15897530 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin
Number of subjects: 210
Study 15897530 — intervention group
Group type: COMPARATOR
Intervention: Rifaximin and Placebo
Number of subjects: 210
Study 14719195 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg subcutaneously every other week
Number of subjects: 636
Study 14719195 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 636
Study 10818278 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg ipsapirone
Number of subjects: 25
Study 10818278 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 25
Study 10818278 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 9009402 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 1984511 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nimodipine
Number of subjects: 213
Study 1984511 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 213
Study 6635439 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral nafcillin plus oral rifampin
Number of subjects: 28
Study 6635439 — intervention group
Group type: COMPARATOR
Intervention: Parenteral nafcillin alone
Number of subjects: 28
Study 6635439 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin in combination with other oral antibiotics
Number of subjects: 28
Study 30569662 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanhuang Xiexin decoction + basic treatment (SX group)
Number of subjects: 121
Study 30569662 — intervention group
Group type: COMPARATOR
Intervention: basic treatment (control group)
Number of subjects: 121
Study 28650204 — intervention group
Group type: EXPERIMENTAL
Intervention: XEN-D0501 (oral, 4 mg twice daily)
Number of subjects: 20
Study 28650204 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 25905795 — intervention group
Group type: EXPERIMENTAL
Intervention: Meningococcal B outer membrane vesicle vaccine
Number of subjects: 0
Study 23943734 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 44
Study 23943734 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 44
Study 21257977 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management (SM) intervention
Number of subjects: 159
Study 21257977 — intervention group
Group type: COMPARATOR
Intervention: Supportive attention (SA) group
Number of subjects: 159
Study 21257977 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC) group
Number of subjects: 159
Study 19767576 — intervention group
Group type: EXPERIMENTAL
Intervention: Tannic acid (TA) treatment (10% and 20%)
Number of subjects: 0
Study 19767576 — intervention group
Group type: EXPERIMENTAL
Intervention: Tannic acid (TA) treatment
Number of subjects: 0
Study 17679563 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocapnic hypoxia (IH, PetO2 approximately 40 mmHg, PetcO2 clamped to 0.4 mmHg above resting values)
Number of subjects: 22
Study 17679563 — intervention group
Group type: COMPARATOR
Intervention: Sham hypoxia (SH, PetO2 103 mmHg without inspired CO2)
Number of subjects: 22
Study 17679563 — intervention group
Group type: EXPERIMENTAL
Intervention: Poikilocapnic hypoxia (PH, PetO2 approximately 40 mmHg; no inspired CO2)
Number of subjects: 22
Study 15450698 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-ER nurse follow-up (two follow-up calls from an experienced ER nurse within 1-2 days and 3-5 days after ER discharge)
Number of subjects: 795
Study 15450698 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-ER nurse follow-up
Number of subjects: 795
Study 15450698 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nurse follow-up)
Number of subjects: 795
Study 15037713 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour bed rest
Number of subjects: 111
Study 15037713 — intervention group
Group type: COMPARATOR
Intervention: Free mobility
Number of subjects: 111
Study 10075899 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimanual flexion and extension movements with alternating in‐ and antiphase
Number of subjects: 0
Study 10075899 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimanual movements with attention and random movements as additional variables
Number of subjects: 0
Study 10075899 — intervention group
Group type: COMPARATOR
Intervention: Condition with strictly regular movement
Number of subjects: 0
Study 7737074 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-generated individualized risk feedback
Number of subjects: 1317
Study 7737074 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk feedback plus behavioral change feedback
Number of subjects: 1317
Study 7737074 — intervention group
Group type: COMPARATOR
Intervention: No feedback
Number of subjects: 1317
Study 7737074 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized risk feedback
Number of subjects: 1317
Study 1828204 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymopentin (three times a week for three consecutive months)
Number of subjects: 20
Study 1828204 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymopentin (continued treatment during phase II)
Number of subjects: 20
Study 1828204 — intervention group
Group type: COMPARATOR
Intervention: Placebo (during phase II)
Number of subjects: 20
Study 6263396 — intervention group
Group type: EXPERIMENTAL
Intervention: Bran crispbread
Number of subjects: 58
Study 6263396 — intervention group
Group type: EXPERIMENTAL
Intervention: Ispaghula drink
Number of subjects: 58
Study 6263396 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 31792478 — intervention group
Group type: EXPERIMENTAL
Intervention: Pit and fissure sealant combined with fluorine protective paint
Number of subjects: 120
Study 31792478 — intervention group
Group type: COMPARATOR
Intervention: Pit and fissure sealant
Number of subjects: 120
Study 27843047 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 23.75mg or 47.5mg q.d.
Number of subjects: 154
Study 26406556 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral cleft lip and palate subjects (UCLP)
Number of subjects: 30
Study 26406556 — intervention group
Group type: COMPARATOR
Intervention: Non-cleft (nonCLP) controls
Number of subjects: 30
Study 24814618 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferiprone
Number of subjects: 0
Study 24814618 — intervention group
Group type: COMPARATOR
Intervention: Deferoxamine
Number of subjects: 0
Study 22927995 — intervention group
Group type: EXPERIMENTAL
Intervention: 21‐h simulated military mission (SMM) with equipment weighing ∼27 kg during battles and ∼43 kg during marches
Number of subjects: 10
Study 22927995 — intervention group
Group type: EXPERIMENTAL
Intervention: 21‐h simulated military mission (SMM)
Number of subjects: 10
Study 19852289 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese medicine (CM)
Number of subjects: 100
Study 19852289 — intervention group
Group type: COMPARATOR
Intervention: Metformin (WM1)
Number of subjects: 100